For the millions of adults living with psychosis-spectrum conditions, negative symptoms — the flattening of motivation, pleasure, and goal-directed behavior — are often more disabling than hallucinations yet far harder to treat. A new mechanistic model published in Neuroscience and Biobehavioral Reviews suggests that childhood trauma may set this trajectory in motion decades before clinical symptoms emerge, with the hippocampus serving as a pivotal but underappreciated link in the chain.
The review synthesizes human and animal research to propose that early adverse experiences structurally and functionally alter the hippocampus in ways that downstream dysregulate dopaminergic circuits — particularly those governing reward learning and sustained motivation. While most reward-dysfunction research in psychosis has centered on striatal pathways, this model repositions the hippocampus as an upstream modulator of those circuits, shaping how the brain anticipates, pursues, and sustains goal-directed behavior. Stress-induced changes to hippocampal volume and connectivity — mediated partly through glucocorticoid receptor sensitivity and GABAergic interneuron loss — are framed as plausible bridges between trauma exposure and the anhedonia and avolition that characterize negative symptom clusters.
This framework carries real interpretive weight because it reframes negative symptoms not primarily as dopamine-deficit phenomena but as downstream consequences of hippocampal circuit disruption — a distinction with direct therapeutic implications. Existing antipsychotics have near-zero efficacy against negative symptoms precisely because they target striatal D2 receptors rather than upstream hippocampal circuitry. The model aligns with growing interest in neuroplasticity-based interventions — including aerobic exercise, cognitive remediation, and glucocorticoid-modulating compounds — that may restore hippocampal function rather than compensate for striatal dysregulation. As a narrative review rather than meta-analysis, causal claims remain inferential, and the heterogeneity of trauma types and psychosis phenotypes limits direct clinical translation. Still, for a field long stuck on symptom suppression, repositioning the hippocampus as a therapeutic target represents a potentially meaningful conceptual shift.
